In contrast, the CCR2 inhibitor CCX872 showed benefit over single-agent chemotherapy in combination with FOLFIRINOX in a phase Ib trial of pancreatic cancer (220). The gene discussed is CCR2; the disease is familial pancreatic carcinoma.